{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:44:05Z","timestamp":1777765445549,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,5,25]],"date-time":"2009-05-25T00:00:00Z","timestamp":1243209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,5,25]],"date-time":"2009-05-25T00:00:00Z","timestamp":1243209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"abstract":"<jats:p>Controlled clinical trials dealing with the first antimycobacterial treatment, published between 1948 and 1971, have been methodologically compared. Three comparable groups have been formed (US-Japan trials, BMRC and IUAT trials with rifampicin in Europe). The significance of individual drugs was calculated by comparison of effects of drug combinations with corresponding monotherapy regimens. The dominance of isoniazid and rifampicin in reduction of mycobacterial population was proved; PAS, thiacetazone and cycloserine mainly prevent the resistance development. Ethambutol, streptomycin and ethionamide form an intermediate group.<\/jats:p>","DOI":"10.1159\/000221806","type":"journal-article","created":{"date-parts":[[2009,5,25]],"date-time":"2009-05-25T11:08:22Z","timestamp":1243249702000},"page":"165-176","source":"Crossref","is-referenced-by-count":0,"title":["Interaction Aspects of Antimycobacterial Drugs in the Chemotherapy of Tuberculosis"],"prefix":"10.1159","author":[{"given":"Ludek","family":"Trnka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jir\u00ec","family":"Tou\u0161ek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,5,25]]},"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/221806","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000221806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:23:55Z","timestamp":1777476235000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000221806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,25]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000221806","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,25]]}}}